Half a Billion Dollars in One Day: Biotech's IPO Window Just Blew Wide Open

Their lead drug, sutacimig, is a bispecific antibody (a molecule designed to grab two different things at once). It essentially acts like a molecular tow truck, dragging a clotting protein to the exact spot on a platelet where it's needed. In Phase 2 trials for Glanzmann thrombasthenia, sutacimig cut the annual rate of treated bleeding events by more than 50%. That's a big deal for patients who currently have no approved preventive treatment.

Hemab is planning a pivotal trial (the kind that can lead to FDA approval) for 2026. Their second program, HMB-002, targets von Willebrand disease and already has first-in-human proof-of-concept data showing it works as intended.

The company originally planned to sell about 11.8 million shares. They upsized twice before settling on 16.75 million shares. That's a roughly 42% increase from the initial plan, which tells you how hungry investors were. Hemab trades under the ticker COAG (because of course a blood clotting company would pick that).

Seaport: The First Neuro IPO of 2026

Seaport became the first biotech focused on brain disorders to go public this year. That distinction matters. Neuropsychiatry has historically been a graveyard for drug developers; the brain is incredibly complex, and failure rates are punishing. Investors tend to treat neuro companies the way you'd treat a friend who says they're going to "definitely finish a marathon this time."

But Seaport has a clever angle. Their platform, called Glyph, redesigns existing drugs that already work in the brain but have annoying problems (poor absorption, liver toxicity, unpredictable blood levels). Instead of inventing new mechanisms from scratch, they're upgrading proven ones.

Their lead candidate, GlyphAllo, is an oral version of allopregnanolone, a natural brain chemical that boosts calming signals in the nervous system. It's already validated for postpartum depression via an IV formulation, but Seaport's version is designed to be taken as a pill. It's currently in a Phase 2b trial for major depressive disorder.

Their second program, GlyphAgo, takes agomelatine (a drug used in Europe for depression but limited by liver safety concerns) and reroutes it through the body's lymphatic system instead of the liver. Phase 1 data showed a 6.8-fold increase in bioavailability and essentially eliminated the liver safety issues that held the original drug back. No serious liver-related side effects in about 130 subjects.

Then there's the wild card: Glyph2BLSD, a non-hallucinogenic version of a molecule related to LSD, targeting treatment-resistant depression and PTSD. It's still preclinical, but it's the kind of thing that makes investors lean forward in their chairs.

Seaport sold 14.16 million shares, well above its initial target of 11.8 million, and trades under ticker SPTX.

What This Means for Biotech's Next Chapter

The dual IPO isn't just a feel-good story for two companies. It's a barometer for the entire sector.

Analysts are interpreting the upsized deals as evidence that institutional order books were multiple times oversubscribed, something that had been rare since 2021. Both stocks posted gains on their first day of trading, which further validates investor appetite. When IPOs pop on day one, it tells every other biotech sitting in the waiting room that the market is ready for them.

The key insight: investors aren't writing blank checks. They're buying clinical-stage companies with real data and clear paths forward. Hemab has Phase 2 results and a pivotal trial on deck. Seaport has a differentiated platform with multiple clinical-stage assets. Neither is a pre-revenue moonshot with nothing but a PowerPoint deck.

This selectivity is the defining feature of the 2026 window. Analysts expect roughly 30 to 35 biotech IPOs this year, a meaningful recovery from 2025 but nowhere near the 2021 frenzy. The companies getting through are the ones with strong venture backing, late-stage pipelines, and stories that make sense on paper and in the clinic.

The Bottom Line

Half a billion dollars raised in a single day by two companies targeting diseases with massive unmet need. One is trying to fix broken blood clotting. The other is reimagining how we treat depression and anxiety. Both managed to upsize their deals in a market that was nearly frozen just 18 months ago.

For the dozens of biotechs still waiting in the wings with late-stage data and hungry investors, the message is clear: the door is open. Just make sure you bring something worth buying.

AstraZeneca's Boldest Bet: Filing for Approval After Failing the Test

AstraZeneca is pushing two drugs toward approval despite Phase 3 failures, betting that subgroup data and supplemental analyses can overcome the biggest hurdle in drug development. The outcome could redefine what "enough evidence" means for the entire industry.